Venetoclax is a speciality medicine duly received approvals from FDA and EMA. This is a research product of AbbVie Inc, which is now commercially available in the US, Europe and Middle Eastern regions. Venclexta and Venclyxto are the commercial brands which are promoted by AbbVie. Genentech also promotes Venetoclax in specific global locations. Venetoclax in India is mostly accessed from Germany or Turkey. Venclyxto in India is noted to be a regular medication prescribed by Haematologists.

Venetoclax is recommended in the treatment of certain types of Leukaemia and Lymphomas. AML and CLL are the well known conditions for which speciality drugs like Venclexta are preferred. Elderly AML patients are a special group of patients considered for this drug. SLL is another indication for which Venclexta in India is procured for CLL and SLL were the initially approved indications, when FDA had granted Venetoclax the breakthrough therapy status. Its relevance is specific to relapsed or refracted cases where patients have not responded well or resistant to earlier treatment. After this initial approval in 2015, FDA had expanded its indications in 2016 for the treatment of CLL patients with 17p deletion. Simultaneously it was granted the orphan drug status. Post 2018 FDA approval, this drug is recommended for CLL and SLL patients irrespective of 17p deletion criteria. However, it still requires failure or progression to a prior therapy. Venetoclax 100mg Tablets are commercially available for import through NPS provisions.